Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Glow (Stabilized Hyaluronic Acid-based Complex) on Healthy Participants

NCT07929870 is registered in ClinicalTrials.gov with Suisselle as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07929870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Glow (Stabilized Hyaluronic Acid-based Complex) on Healthy Participants
Lead sponsor
Suisselle
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 1, 2027
Completion date
August 31, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dark eye circles (periorbital hyperpigmentation), skin hydration in healthy volunteers, skin laxity, skin pigmentation, wrinkle appearance

Arms

As registered; 1 arm.

  • CellBooster® Glow facial injection ExperimentalInjectable

    An initial injection session will be performed at visit 2 (D0). A second injection session will be performed at visit 3 (D14). And a third injection session will be performed at visit 4 (D28).

    CellBooster® Glow (CBG) Class III medical device

    Composition:

    * non-crosslinked Sodium Hyaluronate 18 mg
    * amino acids (Cysteine, Glutathione, Glycine, Lysine, Proline, Valine)
    * vitamins (Sodium Ascorbyl Phosphate, Biotin)
    * phosphate buffer pH 6.8-7.6 q.s

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42. Day -7 to Day 0 and Day 42.

    At each visit, five measurements will be taken on the right cheekbone, a few centimeters below the outer corner of the eye. The recorded value will be the average of the five measurements An improvement of epidermis hydration is defined as an increase higher than 2AU.

Lead sponsor's other trials

Suisselle, most recent start first.

Similar trials

Same condition (Injection Site Reaction) and phase, most recent start first.